Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | TPH1 | P17752 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27489744 | 0.81 | RXRA (0.46) | — | |
| SCHEMBL3890652 | 0.80 | SLC7A5 (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL20274857 | 0.80 | TPH1 (0.60) | TPH1CYP1A2 | |
| SCHEMBL15360000 | 0.79 | CYP1A2 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7205029 | 0.79 | SLC7A5 (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5283089 | 0.79 | SLC7A5 (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL29215396 | 0.78 | CYP1A2 (0.53) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL13957329 | 0.78 | CYP1A2 (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL12128833 | 0.78 | CYP1A2 (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL20422675 | 0.78 | SLC7A5 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | ALPI 4682/4885PKM 3898/4885PTGS1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.